Is LLY a buy, hold, or sell?
LLY carries a valuation grade of Strong Strong Buy. The trailing P/E of 39.0 sits 77% above the Healthcare sector median of 22.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $867–$1,583 — implying a +12% margin of safety at the current price of $1,098.57. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 12% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 25.9% earnings surprise. Analyst estimate revisions are trending upward.
What are LLY's key risk factors?
With a beta of 0.52, LLY exhibits a defensive risk profile relative to the broad market. The 95th-percentile CVaR of -17.8% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 1.8% of total portfolio loss in the worst 5% of months. Net margins of 35.0% are significantly above the Healthcare sector average of 18%, reflecting durable pricing power. Return on equity of 107.5% indicates highly efficient capital allocation. Leverage is moderate with debt-to-equity at 139%.
The options market shows a put/call ratio of 1.62, reflecting a notably bearish skew in derivative positioning. Implied and realized volatility are roughly aligned at 33.8% and 30.4% respectively. Insiders have been net sellers to the tune of $3751.0M recently. While routine dispositions are common, the magnitude bears watching. Short interest is low at 1.1% of float, suggesting limited bearish conviction.
How does LLY fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — LLY carries a beta of 0.52, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, LLY shows the strongest co-movement with PFE (0.33), ABBV (0.28), JNJ (0.28). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The LLY analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning LLY’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
